Paris, France and Cambridge, Massachusetts, USA, March 15, 2019 – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced its unaudited1 consolidated results for the fiscal year ended December 31, 2018: Major milestones achieved during the year: Positive Phase II/III results […]

Read More